Psychstocks is extremely excited to announce its new #1 favorite psilocybin biotechnology stock suggestion: Revive Therapeutics (CSE: RVV). Revive also has a U.S. OTC symbol: RVVTF.
Before we discuss RVV’s psychedelic related intellectual property and upcoming clinical trial of psilocybin, it is important to note that RVV is in the process of conducting Phase 3 clinical trials for a major COVID-19 treatment that we believe is giving RVV most of its current market cap. In our opinion, RVV is not yet being valued as a psychedelic play that is positioned to capitalize on the upcoming surge in interest in psilocybin that will occur as a result of the November 3rd ballot initiatives in Oregon and Washington DC.
You can visit the FDA’s web site by going to: https://clinicaltrials.gov/ct2/show/NCT04504734 and it will tell you all about RVV’s ‘Bucillamine in Treatment of Patients With COVID-19’. This is a Randomized, Double-blind, placebo controlled trial with up to 1,000 patients. RVV at its current price of $0.245 per share with 236,790,599 shares outstanding has a market cap of only USD$44.22 million. Imagine if their Phase 3 trials for Bucillamine are a success and the media attention that RVV would receive worldwide if they are able to successfully receive FDA approval of a new COVID-19 treatment.
What we are most excited about is RVV’s psychedelics therapeutics programs. RVV owns valuable intellectual property related to psilocybin and other psychedelics including its patent-pending oral thin-film delivery system for psilocybin, which offers a unique delivery platform for therapeutic doses of psilocybin into the oral cavity. RVV has received its final set of prototypes and is preparing to scale manufacturing for future clinical studies involving psilocybin and other psychedelic-derived medicines.
It’s good that psilocybin is one of the safest substances you can find – considering how easy it is for a person to take the wrong dosage. Our good friends at the Third Wave (a resource for safe, structured, and responsible psychedelic use) estimate that dry psilocybin mushrooms on average weigh approximately 1/10th the weight of fresh mushrooms containing the same amount of psilocybin. In addition, the caps of psilocybin mushrooms on average are slightly more potent than the stems. In general, psilocybin content varies from mushroom to mushroom even among the same strain. Psilocybe cubensis (the most common strain) has psilocybin contents ranging from 0.37% up to 1.30%.
RVV’s orally dissolvable psilocybin thin-film will not only allow doctors to prescribe exact dosages of psilocybin ranging from 1mg up to 20mg, but it will make psilocybin much easier to consume without the need of water, chewing or swallowing – while allowing it to enter the bloodstream much faster. Psilocybin mushrooms are extremely difficult to chew and swallow and their effects usually don’t kick in until up to one hour later. RVV has what we consider to be the industry’s #1 solution to these issues! Click here to see a list of RVV’s provisional patents filed!
RVV recently entered into a Clinical Trial Agreement with the Board of Regents of the University of Wisconsin System to conduct a clinical study entitled “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder.” The clinical study will be conducted at the University of Wisconsin‒Madison School of Medicine and Public Health and the UW–Madison School of Pharmacy, which holds a Wisconsin special authorization and DEA license to perform clinical research with psilocybin.
RVV announced today that it has signed a supply agreement with Havn Life Sciences to source naturally-derived psychedelic compounds, such as psilocybin, for use in future investigational new drug (IND) enabling studies and clinical trials under the Food and Drug Administration (FDA) guidelines.
Methamphetamine kills thousands of Americans each year and we believe RVV’s psilocybin thin-film could have potential to one day become a major part of the industry standard for treating Methamphetamine addiction!
Past performance is not an indicator of future returns. Psychstocks is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The parent company of Psychstocks has been compensated by RVV USD$30,000 cash and expects to receive 200,000 restricted common shares of RVV stock for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.